Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine

Inclusion Criteria: * Minimum age of 18 years * Informed consent signed and dated by study patient and investigator/authorised physician * Ability to understand the nature and requirements of the study * Treatment with one of the immunoadsorber system GLOBAFFIN® according to the intended use. Exclusion Criteria: General: * Any condition which could interfere with the patient's ability to comply with the study * In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required) * Participation in an interventional clinical study during the preceding 30 days. * Participation in an interventional clinical study with pharmacological active substances (e.g. therapeutic antibodies) during the preceding 60 days. * Any deviation from the intended use Study-specific: Any contraindication listed in the valid instruction for use: * Hypersensitivity or allergy against any materials used in either the immunoadsorber column or the extracorporeal circuit * Inability to withstand the stress of an extracorporeal treatment procedure due to their age, their physical developments or their clinical constitution * Previously demonstrated hypersensitivity associated with therapeutic apheresis * No suitable anticoagulation treatment, such as due to known hypersensitivity to heparin or ACD-A * Haemorrhagic diathesis in which extracorporeal apheresis procedures and anticoagulation performed have a high bleeding hazard * Severe cardiovascular disease, so that extracorporeal treatment is not possible * Acute, systemic infection